Dr David Cavalla - Senior Consultant
David provide consultancy support to the Life Sciences team. He has 30 years' experience in various senior scientific and commercial roles within the pharmaceutical industry and is currently involved with a number of biotech companies at Board level.
Previously, he was founder and CEO of Arachnova Ltd, a company focused on therapeutic switching; previous affiliations included Glaxo Group Research Ltd and Napp Research Centre.
He is the author of Modern Strategy for Pharmaceutical R&D – Towards the Virtual Research Centre, and Off-Label Prescribing: Justifying Unapproved Medicine. He is one of the first advocates of drug re-purposing, and has used this strategy to create three first-in-class developmental products to have successfully passed human proof of concept clinical stages.
David frequently contributes articles on pharmaceutical strategy and is on the editorial board of Drug Discovery Today. Formerly, he was Chairman of the Society for Medicines Research. He obtained a first degree and PhD at the University of Cambridge and spent two years as a visiting Fellow at the NIMH, Washington, DC. He is the author or inventor of more than 70 published papers and patents.